• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

    12/16/21 8:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email

    WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary. Mr. Matsuda joins Arcutis from Halozyme Therapeutics Inc. and succeeds Keith Klein, Esq. who announced his retirement after a successful 30-year industry career. In this role, Mr. Matsuda will oversee all legal and compliance matters for the Company.

    "On behalf of our entire team, we'd like to thank Keith for his considerable contributions to our efforts in establishing Arcutis as a leading medical dermatology company. He has been an invaluable advisor and partner to me during his tenure," said Frank Watanabe, President and CEO of Arcutis.

    Watanabe added, "Mas brings substantial corporate and commercial legal experience within biotechnology, which will be instrumental as we focus on the growth of Arcutis and the potential approval and ultimate commercialization of a diverse pipeline of topical therapies for immune-mediated skin diseases."

    "I am thrilled to be joining Arcutis at this exciting time as we prepare for a potential approval and launch of topical roflumilast cream in psoriasis, and advance pivotal studies across multiple dermatological conditions," said Mas Matsuda. "I look forward to joining this dynamic and experienced team as we deliver on the promise of bringing meaningful innovation for millions of patients with serious skin diseases."

    Mr. Matsuda brings over 20 years of legal experience, including corporate law, compliance, commercial law, employment, and mergers and acquisitions. Previously, he was Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Halozyme Therapeutics, Inc. Prior to Halozyme, Mr. Matsuda worked at Amgen for 18 years in positions of increasing responsibility with his last role serving as Vice President, Law, Global Commercial Operations at Amgen, where he was responsible for strategic commercial legal support to the U.S. Commercial Operations organization, as well as Medical Affairs, Compliance, Global Value, Access & Policy, Global Marketing and Biosimilars division. Mr. Matsuda received his B.S. in Business Administration with a dual emphasis in Corporate Finance and International Finance from the University of Southern California, and his J.D. from University of California, Hastings College of the Law.

    About Arcutis

    Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis' dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, with one NDA submitted to the FDA and three Phase 3 clinical data readouts anticipated by the end of 2022. The company's lead program, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter.

    Forward-Looking Statements

    This press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to be approved for the treatment of adults and adolescents with plaque psoriasis, and the potential for roflumilast to advance the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as our subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

    Contacts:

    Media

    Amanda Sheldon, Head of Corporate Communications

    [email protected]

    Investors

    Eric McIntyre, Head of Investor Relations

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b2384871-f81d-4a6a-b735-dd8f73b6fa09 



    Primary Logo

    Get the next $ARQT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ARQT

    DatePrice TargetRatingAnalyst
    12/30/2024$19.00Buy
    H.C. Wainwright
    8/28/2024$15.00Buy
    Jefferies
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    9/7/2022$46.00Buy
    Needham
    3/17/2022$45.00Buy
    Goldman
    3/2/2022$35.00 → $37.00Overweight
    Morgan Stanley
    More analyst ratings

    $ARQT
    SEC Filings

    See more
    • Arcutis Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)

      6/17/25 4:52:21 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/15/25 5:41:18 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/8/25 5:59:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Welgus Howard G. sold $127,430 worth of shares (9,208 units at $13.84), decreasing direct ownership by 8% to 100,206 units (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      7/2/25 4:25:34 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Welgus Howard G. sold $135,574 worth of shares (10,139 units at $13.37), decreasing direct ownership by 8% to 109,414 units (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/20/25 4:32:21 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/17/25 5:45:01 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis' common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted

      7/3/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

      The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects ZORYVE's proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitorAmong newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis in AAD's focused guideline updateZORYVE is the first FDA-approved branded topical PDE4 inhibitor indicated for AD, plaque psoriasis, and seborrheic dermatitisAD impacts over 16 million adults in the Unit

      6/26/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

      Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitisAtopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first year WESTLAKE VILLAGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT, evaluating the safety and tolerability of investigational ZORYVE (ro

      6/10/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/17/25 5:45:01 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/6/25 8:44:37 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $68,821 worth of shares (5,040 units at $13.65) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      5/23/25 4:04:50 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

      Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

      12/19/23 3:40:08 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

      Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      12/15/23 5:01:31 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

      Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t

      9/27/23 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces Leadership Transition

      Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a leadership change. Ken Lock, who has served as Senior Vice President and Chief Commercial Officer (CCO) since October 2019, is stepping down to attend to personal matters effective June 2, 2023. During this transition period, Arcutis' Vice President of Market Access, Ayisha Jeter, has been appointed interim CCO. Mr. Lock's contributions t

      5/24/23 5:00:03 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

      WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary. Mr. Matsuda joins Arcutis from Halozyme Therapeutics Inc. and succeeds Keith Klein, Esq. who announced his retirement after a successful 30-year industry career. In this role, Mr. Matsuda will oversee all legal and compliance matters for the Company. "On behalf of our entire team, we'd like to thank Keith for his considerable contributions to our efforts in establishing Arcutis as a le

      12/16/21 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Financials

    Live finance-specific insights

    See more
    • Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditionsAll three largest national Pharmacy Benefit Managers (PBMs) covering entire ZORYVE portfolio and Medicaid coverage continues to expandOn April 3, 2025, the patent litigation against Padagis was

      5/6/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

      WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the presentation materials will be available on the "Events" section of The Company's website. An archived replay of the webcast will be available on the Arcutis investor website following th

      4/17/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and including a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returnsFull Year 2024 net product revenue for ZORYVE was $166.5 million, an increase of 471% over the prior year, setting the stage for sustained growth and strong financial position in 2025ZORYVE is now the most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions combined in the United StatesS

      2/25/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/14/24 7:50:59 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/13/24 4:30:25 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/6/24 4:00:53 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

      12/30/24 7:23:09 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

      Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

      8/28/24 7:20:44 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Biotherapeutics upgraded by Mizuho with a new price target

      Mizuho upgraded Arcutis Biotherapeutics from Neutral to Buy and set a new price target of $8.00 from $4.00 previously

      1/3/24 7:32:19 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care